Oral Miltefosine Plus Topical Imiquimod to Treat Cutaneous Leishmaniasis
Launched by FOUNDATION FADER · Jun 22, 2011
Trial Information
Current as of May 19, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Gender: Male or female
- • Age: \>12 yrs of age
- • Presentation: At least 1 lesion must be ulcerative. No more than 3 lesions. Parasitology: Parasitological confirmation of 1 lesion will be made by visualization or culture of leishmania from the biopsy or aspirate of the lesion.
- • No specific or putatively specific therapy (Sb, pentamidine, amphotericin B, imidazoles, allopurinol) in the last 6 months
- Exclusion Criteria:
- • Previous treatment for leishmaniasis
- • concomitant diseases by history
- • abnormal complete blood counts (white blood count, hemoglobin, platelet count), values of liver transaminases (SGOT), kidney function tests (creatinine).
- • pregnancy or breastfeeding or not willing to take contraception for 3 months after the end of treatment.
About Foundation Fader
Foundation Fader is a leading clinical trial sponsor dedicated to advancing innovative therapies and improving patient outcomes through rigorous research and development. With a focus on precision medicine, the organization collaborates with academic institutions, healthcare providers, and industry partners to facilitate the design and execution of clinical studies across various therapeutic areas. Foundation Fader prioritizes ethical practices and patient safety, ensuring that all trials adhere to the highest standards of regulatory compliance. By leveraging cutting-edge technologies and data analytics, Foundation Fader aims to accelerate the translation of scientific discoveries into effective treatments, ultimately enhancing the quality of care for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Santa Cruz, Sc, Bolivia
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials